Viridian Therapeutics (VRDN)
Market Price (12/29/2025): $32.39 | Market Cap: $2.6 BilSector: Health Care | Industry: Biotechnology
Viridian Therapeutics (VRDN)
Market Price (12/29/2025): $32.39Market Cap: $2.6 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% | Trading close to highsDist 52W High is -3.5% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -328 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -464% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 23340% | Weak multi-year price returns3Y Excs Rtn is -65% | Stock price has recently run up significantly6M Rtn6 month market price return is 122% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -99% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 58% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -460%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -461% | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% | ||
| Key risksVRDN key risks include [1] its heavy dependence on successful clinical trial outcomes and regulatory approval for its specific product candidates like veligrotug, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 23340% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -99% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Trading close to highsDist 52W High is -3.5% |
| Weak multi-year price returns3Y Excs Rtn is -65% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -328 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -464% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 122% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 58% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -460%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -461% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% |
| Key risksVRDN key risks include [1] its heavy dependence on successful clinical trial outcomes and regulatory approval for its specific product candidates like veligrotug, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are the key points for why Viridian Therapeutics (VRDN) stock moved significantly from August 31, 2025, to December 29, 2025:
1. The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for veligrotug, Viridian's lead candidate for Thyroid Eye Disease (TED), and granted it Priority Review on December 22, 2025. This decision accelerates the review timeline, setting a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026, and follows veligrotug's earlier Breakthrough Therapy Designation in May 2025, underscoring its potential as a significant improvement over existing treatments.
2. Viridian Therapeutics successfully submitted its Biologics License Application (BLA) for veligrotug for the treatment of TED to the U.S. FDA in late October 2025. This submission was a critical regulatory milestone, supported by positive topline data from two pivotal Phase 3 clinical trials (THRIVE and THRIVE-2) that met all primary and secondary endpoints.
Show more
1. The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for veligrotug, Viridian's lead candidate for Thyroid Eye Disease (TED), and granted it Priority Review on December 22, 2025. This decision accelerates the review timeline, setting a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026, and follows veligrotug's earlier Breakthrough Therapy Designation in May 2025, underscoring its potential as a significant improvement over existing treatments.
2. Viridian Therapeutics successfully submitted its Biologics License Application (BLA) for veligrotug for the treatment of TED to the U.S. FDA in late October 2025. This submission was a critical regulatory milestone, supported by positive topline data from two pivotal Phase 3 clinical trials (THRIVE and THRIVE-2) that met all primary and secondary endpoints.
Show more
Stock Movement Drivers
Fundamental Drivers
The 57.9% change in VRDN stock from 9/28/2025 to 12/28/2025 was primarily driven by a 23109.5% change in the company's Total Revenues ($ Mil).| 9282025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 20.19 | 31.88 | 57.90% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.30 | 70.79 | 23109.51% |
| P/S Multiple | 5401.22 | 36.83 | -99.32% |
| Shares Outstanding (Mil) | 81.59 | 81.78 | -0.23% |
| Cumulative Contribution | 57.90% |
Market Drivers
9/28/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| VRDN | 57.9% | |
| Market (SPY) | 4.3% | 17.6% |
| Sector (XLV) | 15.2% | 11.3% |
Fundamental Drivers
The 122.5% change in VRDN stock from 6/29/2025 to 12/28/2025 was primarily driven by a 23340.1% change in the company's Total Revenues ($ Mil).| 6292025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 14.33 | 31.88 | 122.47% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.30 | 70.79 | 23340.07% |
| P/S Multiple | 3859.81 | 36.83 | -99.05% |
| Shares Outstanding (Mil) | 81.34 | 81.78 | -0.54% |
| Cumulative Contribution | 122.46% |
Market Drivers
6/29/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| VRDN | 122.5% | |
| Market (SPY) | 12.6% | 18.3% |
| Sector (XLV) | 17.0% | 25.4% |
Fundamental Drivers
The 63.9% change in VRDN stock from 12/28/2024 to 12/28/2025 was primarily driven by a 23340.1% change in the company's Total Revenues ($ Mil).| 12282024 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 19.45 | 31.88 | 63.91% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.30 | 70.79 | 23340.07% |
| P/S Multiple | 4277.72 | 36.83 | -99.14% |
| Shares Outstanding (Mil) | 66.42 | 81.78 | -23.13% |
| Cumulative Contribution | 55.14% |
Market Drivers
12/28/2024 to 12/28/2025| Return | Correlation | |
|---|---|---|
| VRDN | 63.9% | |
| Market (SPY) | 17.0% | 33.0% |
| Sector (XLV) | 13.8% | 36.5% |
Fundamental Drivers
The 10.3% change in VRDN stock from 12/29/2022 to 12/28/2025 was primarily driven by a 3663.4% change in the company's Total Revenues ($ Mil).| 12292022 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 28.90 | 31.88 | 10.31% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1.88 | 70.79 | 3663.37% |
| P/S Multiple | 518.42 | 36.83 | -92.90% |
| Shares Outstanding (Mil) | 33.74 | 81.78 | -142.38% |
| Cumulative Contribution | -213.32% |
Market Drivers
12/29/2023 to 12/28/2025| Return | Correlation | |
|---|---|---|
| VRDN | 46.4% | |
| Market (SPY) | 48.4% | 27.7% |
| Sector (XLV) | 17.8% | 28.5% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VRDN Return | 129% | 20% | 48% | -25% | -12% | 68% | 348% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| VRDN Win Rate | 42% | 67% | 50% | 33% | 25% | 83% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| VRDN Max Drawdown | -24% | -35% | -52% | -62% | -47% | -43% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | VRDN | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -70.4% | -25.4% |
| % Gain to Breakeven | 238.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -82.2% | -33.9% |
| % Gain to Breakeven | 462.0% | 51.3% |
| Time to Breakeven | 1,026 days | 148 days |
| 2018 Correction | ||
| % Loss | -97.4% | -19.8% |
| % Gain to Breakeven | 3757.9% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Viridian Therapeutics's stock fell -70.4% during the 2022 Inflation Shock from a high on 1/26/2023. A -70.4% loss requires a 238.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
AI Analysis | Feedback
- They are like a clinical-stage Regeneron, specializing in developing new treatments for autoimmune and inflammatory conditions such as Thyroid Eye Disease.
- Think of them as a biotech aiming to develop a superior drug for Thyroid Eye Disease, competing with treatments from larger companies like Amgen.
AI Analysis | Feedback
- VRDN-001: An investigational insulin-like growth factor-1 receptor (IGF-1R) antibody being developed as an intravenous therapy for active and chronic thyroid eye disease (TED).
- VRDN-002: A next-generation, longer-half-life investigational IGF-1R antibody designed for subcutaneous administration, aiming for less frequent dosing in active and chronic thyroid eye disease (TED).
AI Analysis | Feedback
Viridian Therapeutics (VRDN) is a clinical-stage biotechnology company focused on developing novel treatments for serious diseases. As of the current date, Viridian Therapeutics does not have any approved products on the market generating commercial sales. Therefore, it does not currently have major customers in the traditional sense of companies or individuals purchasing its products. Its primary activities involve research and development, clinical trials, and seeking regulatory approval for its drug candidates.Viridian Therapeutics (VRDN) is a clinical-stage biotechnology company. As such, it is focused on the research and development of drug candidates and does not currently have any approved products on the market that generate commercial sales.
Therefore, Viridian Therapeutics does not have major customers, either other companies or individual consumers, from the sale of products or services at this time.
AI Analysis | Feedback
null
AI Analysis | Feedback
Below is the management team for Viridian Therapeutics:Steve Mahoney, President and Chief Executive Officer
Steve Mahoney has over two decades of experience in operational, financial, commercial, legal, and transactional roles, successfully scaling organizations from their founding through commercial stages. Before joining Viridian Therapeutics, he served as Chief Financial and Operating Officer of Magenta Therapeutics. He was also part of the founding team of Kiniksa Pharmaceuticals, where he held the position of President and Chief Operating Officer. Earlier in his career, Mr. Mahoney was the Chief Commercial Officer of Synageva Biopharma, a company focused on ultrarare diseases, where he managed operations, commercial launch preparations, legal, and corporate development. He also spent about ten years as a commercial attorney with Genzyme Corporation and was a corporate attorney with Mintz Levin.
Seth Harmon, Chief Financial Officer
Seth Harmon serves as the Chief Financial Officer of Viridian Therapeutics. Prior to this role, he was the Senior Vice President of Finance and Accounting at Viridian Therapeutics.
Tom Beetham, Chief Operating Officer
Tom Beetham joined Viridian Therapeutics as Chief Operating Officer in 2023. He brings over 20 years of experience in operations, business development, strategy, and legal within the biopharmaceutical industry. Previously, Mr. Beetham was the Chief Legal Officer of Magenta Therapeutics, Inc. He was also part of the founding team of Kiniksa Pharmaceuticals, where he served as Executive Vice President, Corporate Development and Operations, and Chief Legal Officer, overseeing multiple functions.
Shan Wu, Ph.D., Chief Business Officer
Shan Wu is the Chief Business Officer at Viridian Therapeutics. Dr. Wu has a background in business development within the biotechnology sector.
Radhika Tripuraneni, M.D., Chief Medical Officer
Dr. Radhika Tripuraneni joined Viridian Therapeutics in 2024 as a consultant and was appointed Chief Medical Officer in 2025. She has over 25 years of experience in drug development, covering clinical science, medical affairs, and business development. Most recently, Dr. Tripuraneni worked as an independent consultant, advising venture capital firms, investment funds, and biotech companies on strategic clinical development plans and investment diligence.
AI Analysis | Feedback
The key risks to Viridian Therapeutics (VRDN) are primarily centered around its nature as a biopharmaceutical company in clinical development.
- Clinical Development and Regulatory Approval Risks: As a biopharmaceutical company, Viridian Therapeutics' success is heavily dependent on the successful outcome of its ongoing clinical trials for product candidates such as veligrotug (VRDN-001), VRDN-003, and VRDN-006. There is an inherent risk that clinical trials may fail to demonstrate sufficient safety and efficacy, or that preliminary data may not reflect final results. Any delays or failures in these trials, or in obtaining necessary regulatory approvals from bodies like the FDA, could materially harm the company's business prospects and significantly delay or prevent the commercialization of its product candidates. Even if approved, regulatory authorities may impose additional requirements or could withdraw approval if compliance or post-market issues arise.
- Financial Risks and Need for Additional Capital: Viridian Therapeutics has a history of significant net losses and anticipates that these losses will continue. The company expects to require substantial additional capital to fund its operations, with previous reports indicating a need for funding beyond the second half of 2027. Should Viridian be unable to raise this necessary capital through equity offerings, debt financings, or strategic collaborations, it could be forced to delay, reduce, or even eliminate its critical research and development programs or future commercialization efforts. The company's financial health shows concerning profitability metrics, including negative revenue growth, operating margin, and net margin.
- Competition and Market Risks: Viridian Therapeutics operates within a highly competitive and rapidly evolving biopharmaceutical landscape. The company faces significant market risks, including competition from existing therapies and other product candidates being developed by competitors. The success of Viridian's product candidates, even if approved, could be limited by the emergence of more effective or safer therapies, or by pricing pressures and changes in healthcare regulations.
AI Analysis | Feedback
The clear emerging threat to Viridian Therapeutics (VRDN) is the potential approval and market penetration of **efgartigimod (Vyvgart)** for Thyroid Eye Disease (TED), developed by argenx. Efgartigimod is an FcRn antagonist, a mechanism of action distinct from Viridian's IGF-1R inhibitors (VRDN-001 and VRDN-002).
Efgartigimod is currently in a Phase 3 clinical trial (ADHERE trial) for TED. If successful, it would introduce a new, effective therapeutic option that competes directly with the IGF-1R class. Unlike Viridian, which aims to improve upon an existing mechanism (teprotumumab/Tepezza), efgartigimod offers a fundamentally different approach to addressing the autoimmune pathology of TED. This could disrupt the market by providing an alternative that may offer different benefits in terms of efficacy, safety, or patient preference, potentially capturing significant market share and challenging the dominance of IGF-1R inhibitors in the TED treatment landscape.
AI Analysis | Feedback
Viridian Therapeutics' primary products in development, VRDN-001 (veligrotug) and VRDN-003, are focused on treating Thyroid Eye Disease (TED). The company is also developing VRDN-006 and VRDN-008, a portfolio of neonatal Fc receptor (FcRn) inhibitors for autoimmune diseases.
The addressable market for Thyroid Eye Disease (TED) is substantial and is projected to grow globally:
- The global thyroid eye disease market was valued at $2.3 billion in 2023 across seven major markets (United States, EU4, United Kingdom, and Japan), with anticipated continued growth through 2034.
- Another estimate places the global thyroid eye disease market size at $2,122.9 million in 2023, with projections to reach $4,139.7 million by 2034, demonstrating a compound annual growth rate (CAGR) of 6.26% during the 2024-2034 period.
- Similarly, the market size was valued at $2.26 billion in 2024 and is predicted to reach $4.02 billion by 2034, with a 6.0% CAGR between 2025 and 2034.
- Specifically for the top 7 markets (US, EU4, UK, and Japan), the market reached $2,255.8 million in 2024 and is expected to grow to $4,458.8 million by 2035, at a CAGR of 6.40% from 2025 to 2035.
The United States represents the largest segment of the Thyroid Eye Disease market. The North American TED treatment market was valued at $0.85 billion in 2024 and is expected to reach $1.5 billion by 2035.
While Viridian Therapeutics is also developing FcRn inhibitors for other autoimmune diseases, specific addressable market sizes for these broader autoimmune indications were not distinctly quantified in the provided search results.
AI Analysis | Feedback
Viridian Therapeutics (VRDN) is poised for significant revenue growth over the next 2-3 years, driven by several key pipeline advancements and market expansion strategies. Here are the expected drivers of future revenue growth: * U.S. Commercial Launch of Veligrotug (VRDN-001) for Thyroid Eye Disease (TED): Viridian anticipates the potential U.S. approval and commercial launch of veligrotug (formerly VRDN-001), an intravenous therapy for active and chronic TED, by mid-2026, following its Biologics License Application (BLA) submission and Breakthrough Therapy Designation. Analysts are optimistic about veligrotug's competitive profile in the TED market, considering current consensus revenue estimates for 2026 to be conservative. * Development and Future Launch of VRDN-003 for TED: The company is advancing VRDN-003, a next-generation, subcutaneous IGF-1R antibody designed for improved convenience and a longer half-life compared to veligrotug. Positive Phase 3 trial readouts for VRDN-003 in active and chronic TED are expected in Q1 and Q2 2026, respectively, with a BLA submission planned for year-end 2026. This product has the potential to become a best-in-class subcutaneous therapy, further penetrating the TED market. * Expansion of FcRn Inhibitor Portfolio (VRDN-006 and VRDN-008): Beyond TED, Viridian is progressing its novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and the next-generation VRDN-008, for potential development across multiple autoimmune diseases. VRDN-008, with its extended half-life, could offer improved dosing convenience and deeper IgG lowering. Healthy volunteer data for VRDN-008 is anticipated in the second half of 2026, signaling continuous pipeline advancement and potential for future revenue streams from new indications. * International Market Penetration for IGF-1R Products: Viridian also expects to expand its IGF-1R class products (veligrotug and VRDN-003) into ex-U.S. markets in the coming years. The company has already secured an exclusive agreement with Kissei Pharmaceutical for the development and commercialization of veligrotug and VRDN-003 in Japan, including an initial payment and potential milestone payments. This strategic partnership opens up international revenue opportunities.AI Analysis | Feedback
Share Issuance
- In October 2025, Viridian Therapeutics completed a public offering of common stock, generating gross proceeds of approximately $289.1 million from the sale of 13,138,750 shares.
- The proceeds from this offering are intended to support commercial launch activities for veligrotug and VRDN-003, fund ongoing research and development efforts, and cover general corporate purposes.
- A proposed underwritten public offering in October 2025 also included Series B non-voting convertible preferred stock, designed to raise capital without immediate common shareholder dilution, though it introduces potential future dilution upon conversion.
Inbound Investments
- In October 2025, Viridian secured a royalty financing agreement with DRI Healthcare Acquisitions LP, providing up to $300 million in total capital, which included an upfront payment of $55 million and $115 million in near-term milestones.
- The company amended its credit facility with Hercules Capital, Inc. in October 2025, making up to $300 million available and providing $30 million in immediate proceeds after repaying a prior facility.
- In July 2025, Viridian entered an exclusive license agreement with Kissei Pharmaceutical for veligrotug and VRDN-003 in Japan, receiving an upfront payment of $70 million and potential future milestones up to $315 million.
Capital Expenditures
- Viridian Therapeutics' net cash used for investing activities was $(1.37) million for the 2024 fiscal year.
- Research and development expenses significantly increased, reaching $86.3 million in Q3 2025, up from $69.2 million in Q3 2024, primarily driven by the advancement of its clinical pipeline.
- The primary focus of these expenditures is the progression of multiple ongoing phase 3 clinical trials for veligrotug and VRDN-003, and a phase 1 clinical trial for VRDN-006, along with increased personnel costs.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to VRDN. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Viridian Therapeutics
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 55.02 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Price Behavior
Price Behavior
| Market Price | $31.88 | |
| Market Cap ($ Bil) | 2.6 | |
| First Trading Date | 06/18/2014 | |
| Distance from 52W High | -3.5% | |
| 50 Days | 200 Days | |
| DMA Price | $28.54 | $19.27 |
| DMA Trend | up | up |
| Distance from DMA | 11.7% | 65.4% |
| 3M | 1YR | |
| Volatility | 49.2% | 53.3% |
| Downside Capture | -3.89 | 95.67 |
| Upside Capture | 217.24 | 130.03 |
| Correlation (SPY) | 19.6% | 33.1% |
VRDN Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.14 | 0.61 | 0.49 | 0.77 | 0.97 | 1.03 |
| Up Beta | 0.96 | 0.92 | 0.22 | 0.85 | 0.83 | 0.85 |
| Down Beta | 0.18 | 0.36 | 0.03 | 0.03 | 0.80 | 0.98 |
| Up Capture | 263% | 237% | 259% | 255% | 166% | 125% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 13 | 26 | 37 | 69 | 121 | 356 |
| Down Capture | -162% | -46% | -49% | 1% | 106% | 105% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 7 | 16 | 26 | 56 | 126 | 387 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of VRDN With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| VRDN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 67.5% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 53.0% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 1.16 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 36.5% | 32.8% | -1.0% | 10.9% | 23.0% | 23.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of VRDN With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| VRDN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 9.9% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 68.0% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | 0.41 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 20.7% | 23.3% | 4.2% | 3.0% | 22.9% | 12.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of VRDN With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| VRDN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -14.8% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 133.8% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.32 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 11.7% | 11.2% | 0.3% | 2.6% | 8.0% | 6.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2025 | 8.3% | 26.1% | 42.0% |
| 8/6/2025 | -1.4% | 3.0% | 6.9% |
| 2/27/2025 | -1.5% | -1.6% | -5.5% |
| 11/12/2024 | -12.8% | -20.9% | -26.2% |
| 8/8/2024 | -1.8% | -7.9% | -8.5% |
| 5/8/2024 | -1.6% | -3.1% | -19.2% |
| 2/27/2024 | 2.9% | -7.6% | -10.7% |
| 11/13/2023 | 8.8% | 15.7% | 37.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 7 | 7 |
| # Negative | 9 | 10 | 10 |
| Median Positive | 5.2% | 15.7% | 20.2% |
| Median Negative | -6.8% | -8.3% | -17.6% |
| Max Positive | 49.4% | 60.1% | 51.1% |
| Max Negative | -16.7% | -39.5% | -26.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/06/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/06/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/03/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/12/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/08/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/08/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 02/27/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/13/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/08/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/10/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/09/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/14/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/15/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/13/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/11/2022 | 10-K (12/31/2021) |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Fairmount Funds Management LLC | 10272025 | Buy | 22.00 | 454,545 | 9,999,990 | 86,118,076 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.